NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
STLN
Starling Oncology, Inc.
STLN has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
STLN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Stable | |
| Unavailable |
STLN's revenue is currently healthy, and its profitability and cash flow are stable. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
STLN PE Valuation
STLN has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
STLN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
STLN has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over STLN on earnings quality, reporting a profit while its opponent remains loss making.
STLN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.27 | +$0.37 |
| Q2 2026 | -$0.28 | +$0.40 |
| Q1 2026 | -$0.35 | +$0.35 |
| Q4 2025 | -$0.54 | +$0.17 |
| Q3 2025 | -$0.64 | +$0.14 |
| Q2 2025 | -$0.68 | +$0.11 |
| Q1 2025 | -$0.70 | +$0.11 |
| Q4 2024 | -$0.71 | +$0.21 |
STLN is still losing money, but far less than before: $0.27 per share over the past year, against $0.92 at its worst in late 2023.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over STLN on profitability, with a higher operating margin.
STLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $169.8M | +24% |
| Q2 2026 | $161.3M | +35% |
| Q1 2026 | $147.4M | +41% |
| Q4 2025 | $142M | +42% |
| Q3 2025 | $136.6M | +37% |
| Q2 2025 | $119.8M | +22% |
| Q1 2025 | $104.4M | +10% |
| Q4 2024 | $100.3M | +17% |
STLN has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1.8% | +4.1 points |
| Q2 2026 | -2.9% | +6.5 points |
| Q1 2026 | -4.4% | +5.1 points |
| Q4 2025 | -4.9% | +7 points |
| Q3 2025 | -5.9% | +8 points |
| Q2 2025 | -9.4% | +7.2 points |
| Q1 2025 | -9.5% | +9.5 points |
| Q4 2024 | -12% | +5.9 points |
STLN's operating margin was −1.8% last quarter, up 4.1 points from the same quarter a year ago, near the top of its range since 2022.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
STLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.9M | +$22.1M |
| Q2 2026 | $11M | +$22.4M |
| Q1 2026 | -$3.3M | +$2.1M |
| Q4 2025 | $2.2M | -3.2% |
| Q3 2025 | -$13.2M | -1184% |
| Q2 2025 | -$11.4M | +$6.1M |
| Q1 2025 | -$5.3M | +$11.2M |
| Q4 2024 | $2.2M | +$7M |
STLN has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over STLN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
STLN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.6% | +1.7M shares |
| 1 year | +7.4% | +7.3M shares |
| 3 years | +43% | +31.3M shares |
| 5 years | +1721% | +99M shares |
STLN has 105M diluted shares, up 7.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $125,000 |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $9M |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
STLN Net Leverage
STLN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
STLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.7 | Neutral |
| Stochastic | 31.0 | Neutral |
STLN's weekly RSI is 37 (neutral) and its Stochastic is 31 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
STLN PE vs Healthcare Sector
STLN has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
STLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.83 | 36% below |
| 20 week MA | $5.88 | 36% below |
| 50 week MA | $4.53 | 17% below |
| 100 week MA | $3.49 | 7.4% above |
| 200 week MA | $2.25 | 67% above |
STLN has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
STLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.84 | $10.8 | +9.8% |
| 2021 | $10.8 | $10.4 | -3.3% |
| 2022 | $10.4 | $1.60 | -85% |
| 2023 | $1.60 | $2.04 | +27% |
| 2024 | $2.04 | $0.32 | -84% |
| 2025 | $0.32 | $3.64 | +1038% |
| 2026 YTD | $3.64 | $3.75 | +3% |
STLN has the edge over NVO on returns for 2026, with the stronger performance.